<DOC>
	<DOCNO>NCT01623609</DOCNO>
	<brief_summary>The purpose study demonstrate Bioequivalence , assess food administration Pharmacokinetics naloxegol .</brief_summary>
	<brief_title>Open Label , Healthy Volunteers , Bioequivalence Study With Naloxegol</brief_title>
	<detailed_description>A Phase I , Randomised , Open-label , 3 way Cross-over Study Healthy Volunteers Demonstrate Bioequivalence Naloxegol 25 mg Commercial Phase III Formulations Assess Effect Food Administration Pharmacokinetics Commercial Formulation .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Naloxegol</mesh_term>
	<criteria>Female nonpregnant , nonlactating . Volunteers suitable vein cannulation repeat venipuncture . Male healthy volunteer willing use barrier contraception ie , condom , first day dose 3 month dose investigational product . The female partner use contraception period . History clinically significant disease disorder . Any clinically significant illness , medical/surgical procedure trauma within 4 week first administration investigational product . Volunteers smoke used nicotine product within previous 3 month date screening . Any clinically significant abnormality clinical chemistry , haematology , urinalysis result judge Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>Naloxegol</keyword>
	<keyword>Bioequivalence</keyword>
</DOC>